Abstract
Human leukocyte cultures stimulated by phytohemagglutinin (PHA) or purified protein derivative (PPD) produce and release a procoagulant (PCF) that can correct the clotting defect in Factor VIII, but not Factor VII- or Factor X-deficient plasma. Since exogenous anticoagulants can suppress cellular immune responses, it is likely that certain patients with coagulation defects may have impaired reactions as well. The site of action of PCF, as elucidated by our in vitro studies, suggested that Factor VIII-deficient individuals should have normal delayed hypersensitivity responses, but Factor VII-deficient individuals should have diminished reactivity. In the limited number of patients available for study, this proved to be the case. These findings demonstrate the existence of a procoagulant that is either a lymphokine or lymphokine-induced monokine and provide indirect evidence for its role in in vivo reactions of cellular immunity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
